Share Price and Basic Stock Data
Last Updated: December 6, 2025, 8:59 pm
| PEG Ratio | -432.03 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gujarat Alkalies & Chemicals Ltd (GACL) operates in the inorganic chemicals segment, primarily producing caustic soda and soda ash, which are essential inputs for a variety of industries. The company reported revenues of ₹4,516 Cr for FY 2023, reflecting a substantial growth trajectory from ₹3,759 Cr in FY 2022. However, the subsequent fiscal year, FY 2024, saw a decline in revenues to ₹3,807 Cr, raising questions about the sustainability of this growth. The latest trailing twelve months (TTM) revenue stands at ₹4,201 Cr, indicating a slight recovery but still falling short of prior peaks. The company’s quarterly sales have shown fluctuations, with the most recent quarter (September 2023) recording ₹971 Cr, down from ₹1,138 Cr in March 2023. This inconsistency in revenue generation suggests that GACL might be facing challenges in maintaining its sales momentum, possibly due to market conditions or operational inefficiencies.
Profitability and Efficiency Metrics
The profitability metrics of GACL paint a concerning picture, especially with a reported net loss of ₹65 Cr for FY 2025, following a loss of ₹237 Cr in FY 2024. This downturn is reflected in the operating profit margin (OPM), which plummeted to just 1% in FY 2024, and marginally improved to 7% in FY 2025. The company’s interest coverage ratio (ICR) is a more comforting figure at 8.95x, indicating that GACL can comfortably meet its interest obligations despite the losses. However, the return on equity (ROE) and return on capital employed (ROCE) are notably low at 1.13% and 0.34%, respectively, which raises concerns about the efficient use of capital. The cash conversion cycle (CCC) of 19 days suggests that the company is managing its working capital relatively efficiently, but the overall profitability challenges overshadow this strength.
Balance Sheet Strength and Financial Ratios
Examining GACL’s balance sheet reveals a mixed picture. The company has total reserves amounting to ₹5,497 Cr, which provides a buffer against operational losses. However, with borrowings at ₹637 Cr and a debt-to-equity ratio of 0.09, the financial leverage appears manageable. The price-to-book value (P/BV) ratio stands at 0.75x, indicating that the stock is trading below its book value, which may attract value investors. Yet, the low return ratios suggest that even with a solid asset base, GACL is struggling to generate adequate returns for shareholders. Furthermore, the company has seen an increase in other liabilities, which have risen to ₹2,002 Cr in FY 2025, indicating potential financial strain. Investors should keep an eye on how effectively GACL can leverage its assets to improve profitability in the coming periods.
Shareholding Pattern and Investor Confidence
GACL’s shareholding structure reflects a stable ownership landscape, with promoters holding 46.28% of the equity, signifying strong management control. Institutional interest, while modest, has seen fluctuations, with Foreign Institutional Investors (FIIs) currently holding 1.02% and Domestic Institutional Investors (DIIs) at 4.52%. The public holds a significant stake of 48.16%, demonstrating a broad base of retail investor participation. This distribution indicates that while the core management retains control, there is also a healthy level of public investment, which can be a double-edged sword. On one hand, it suggests confidence in the company’s potential; on the other, persistent losses may lead to disenchantment among retail shareholders, affecting future stock performance and investor sentiment.
Outlook, Risks, and Final Insight
Looking ahead, GACL faces a challenging yet potentially rewarding path. The company must navigate the dual pressures of fluctuating revenues and profitability while leveraging its asset base effectively. The risks of ongoing operational losses, alongside market volatility in the chemicals sector, could weigh heavily on investor confidence. Furthermore, the need for capital efficiency is paramount, given the low return ratios. Investors should consider the potential for recovery if GACL can stabilize its operations and enhance profitability. However, caution is warranted due to the current financial instability. A prudent approach would involve closely monitoring quarterly performance, strategic initiatives to boost operational efficiency, and market conditions. The chemical industry’s cyclical nature adds another layer of complexity, making it essential for investors to remain vigilant and adaptable in their assessment of GACL’s future prospects.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Gujarat Alkalies & Chemicals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Caprolactam Chemicals Ltd | 27.6 Cr. | 60.1 | 69.0/37.5 | 2,764 | 11.6 | 0.00 % | 0.48 % | 13.7 % | 10.0 |
| Standard Industries Ltd | 106 Cr. | 16.4 | 31.1/15.8 | 20.4 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
| Gujarat Alkalies & Chemicals Ltd | 3,795 Cr. | 517 | 823/484 | 25,303 | 759 | 3.06 % | 0.34 % | 1.13 % | 10.0 |
| GHCL Ltd | 5,760 Cr. | 600 | 779/511 | 10.1 | 378 | 2.00 % | 24.2 % | 18.6 % | 10.0 |
| Tata Chemicals Ltd | 19,720 Cr. | 774 | 1,139/756 | 60.5 | 877 | 1.42 % | 3.96 % | 1.20 % | 10.0 |
| Industry Average | 6,020.20 Cr | 411.42 | 5,637.16 | 389.00 | 1.12% | 7.11% | 8.14% | 9.17 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,128 | 1,127 | 1,123 | 1,138 | 913 | 971 | 921 | 1,002 | 977 | 991 | 1,029 | 1,075 | 1,105 |
| Expenses | 778 | 969 | 885 | 936 | 882 | 955 | 941 | 998 | 923 | 945 | 951 | 974 | 1,010 |
| Operating Profit | 351 | 159 | 238 | 202 | 31 | 16 | -20 | 4 | 54 | 46 | 78 | 101 | 95 |
| OPM % | 31% | 14% | 21% | 18% | 3% | 2% | -2% | 0% | 6% | 5% | 8% | 9% | 9% |
| Other Income | 6 | 22 | 6 | 8 | 12 | 71 | 5 | 3 | 3 | 49 | 15 | 24 | 8 |
| Interest | 2 | 3 | 8 | 8 | 10 | 11 | 11 | 12 | 11 | 11 | 10 | 18 | 14 |
| Depreciation | 50 | 60 | 79 | 88 | 89 | 95 | 96 | 97 | 97 | 100 | 98 | 97 | 102 |
| Profit before tax | 305 | 118 | 157 | 115 | -57 | -18 | -123 | -102 | -50 | -16 | -15 | 10 | -12 |
| Tax % | 37% | 49% | 44% | 38% | 0% | -0% | -6% | -55% | -11% | 15% | -27% | 13% | 15% |
| Net Profit | 191 | 61 | 87 | 71 | -57 | -18 | -115 | -46 | -45 | -18 | -11 | 9 | -14 |
| EPS in Rs | 25.99 | 8.24 | 11.87 | 9.67 | -7.78 | -2.50 | -15.68 | -6.29 | -6.06 | -2.48 | -1.53 | 1.20 | -1.88 |
Last Updated: August 20, 2025, 10:00 am
Below is a detailed analysis of the quarterly data for Gujarat Alkalies & Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,105.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,075.00 Cr. (Mar 2025) to 1,105.00 Cr., marking an increase of 30.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,010.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 974.00 Cr. (Mar 2025) to 1,010.00 Cr., marking an increase of 36.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 95.00 Cr.. The value appears to be declining and may need further review. It has decreased from 101.00 Cr. (Mar 2025) to 95.00 Cr., marking a decrease of 6.00 Cr..
- For OPM %, as of Jun 2025, the value is 9.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00%.
- For Other Income, as of Jun 2025, the value is 8.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 16.00 Cr..
- For Interest, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 102.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 97.00 Cr. (Mar 2025) to 102.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 10.00 Cr. (Mar 2025) to -12.00 Cr., marking a decrease of 22.00 Cr..
- For Tax %, as of Jun 2025, the value is 15.00%. The value appears to be increasing, which may not be favorable. It has increased from 13.00% (Mar 2025) to 15.00%, marking an increase of 2.00%.
- For Net Profit, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 23.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.88. The value appears to be declining and may need further review. It has decreased from 1.20 (Mar 2025) to -1.88, marking a decrease of 3.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:15 am
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,995 | 2,070 | 2,455 | 3,161 | 2,725 | 2,429 | 3,759 | 4,516 | 3,807 | 4,073 | 4,201 |
| Expenses | 1,660 | 1,622 | 1,669 | 2,046 | 2,148 | 2,072 | 2,774 | 3,568 | 3,775 | 3,793 | 3,880 |
| Operating Profit | 335 | 448 | 786 | 1,115 | 577 | 357 | 984 | 949 | 32 | 279 | 321 |
| OPM % | 17% | 22% | 32% | 35% | 21% | 15% | 26% | 21% | 1% | 7% | 8% |
| Other Income | 45 | 56 | 106 | 62 | 90 | 67 | 46 | 42 | 90 | 92 | 97 |
| Interest | 10 | 13 | 15 | 21 | 14 | 15 | 6 | 19 | 45 | 51 | 53 |
| Depreciation | 107 | 111 | 127 | 140 | 162 | 174 | 198 | 276 | 377 | 392 | 398 |
| Profit before tax | 262 | 381 | 749 | 1,016 | 491 | 235 | 826 | 695 | -300 | -71 | -33 |
| Tax % | 16% | 19% | 29% | 32% | 32% | 29% | 32% | 41% | -21% | -9% | |
| Net Profit | 220 | 307 | 534 | 690 | 332 | 166 | 560 | 410 | -237 | -65 | -34 |
| EPS in Rs | 29.90 | 41.85 | 72.78 | 93.98 | 45.22 | 22.57 | 76.22 | 55.78 | -32.25 | -8.87 | -4.69 |
| Dividend Payout % | 15% | 12% | 9% | 9% | 18% | 35% | 13% | 42% | -43% | -178% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 39.55% | 73.94% | 29.21% | -51.88% | -50.00% | 237.35% | -26.79% | -157.80% | 72.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | 34.40% | -44.73% | -81.10% | 1.88% | 287.35% | -264.14% | -131.02% | 230.38% |
Gujarat Alkalies & Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 3% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 85% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | -15% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 1% |
| Last Year: | -1% |
Last Updated: September 5, 2025, 5:30 am
Balance Sheet
Last Updated: December 4, 2025, 1:19 am
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 73 | 73 | 73 | 73 | 73 | 73 | 73 | 73 | 73 | 73 | 73 |
| Reserves | 2,854 | 3,282 | 3,748 | 4,222 | 4,522 | 5,301 | 5,826 | 6,066 | 6,002 | 5,596 | 5,497 |
| Borrowings | 295 | 353 | 291 | 247 | 205 | 498 | 594 | 597 | 544 | 561 | 637 |
| Other Liabilities | 671 | 726 | 859 | 988 | 1,090 | 1,282 | 1,484 | 1,599 | 1,404 | 1,756 | 2,002 |
| Total Liabilities | 3,894 | 4,435 | 4,970 | 5,531 | 5,891 | 7,154 | 7,977 | 8,335 | 8,023 | 7,987 | 8,209 |
| Fixed Assets | 1,821 | 2,073 | 2,104 | 2,300 | 2,610 | 2,587 | 2,702 | 4,250 | 4,617 | 4,584 | 4,522 |
| CWIP | 83 | 151 | 252 | 307 | 445 | 1,109 | 1,787 | 544 | 95 | 79 | 37 |
| Investments | 854 | 1,016 | 1,145 | 1,065 | 1,242 | 2,092 | 2,110 | 1,831 | 2,093 | 1,976 | 2,044 |
| Other Assets | 1,136 | 1,196 | 1,469 | 1,858 | 1,594 | 1,366 | 1,379 | 1,710 | 1,218 | 1,348 | 1,607 |
| Total Assets | 3,894 | 4,435 | 4,970 | 5,531 | 5,891 | 7,154 | 7,977 | 8,335 | 8,023 | 7,987 | 8,209 |
Below is a detailed analysis of the balance sheet data for Gujarat Alkalies & Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 73.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 73.00 Cr..
- For Reserves, as of Sep 2025, the value is 5,497.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,596.00 Cr. (Mar 2025) to 5,497.00 Cr., marking a decrease of 99.00 Cr..
- For Borrowings, as of Sep 2025, the value is 637.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 561.00 Cr. (Mar 2025) to 637.00 Cr., marking an increase of 76.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,002.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,756.00 Cr. (Mar 2025) to 2,002.00 Cr., marking an increase of 246.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8,209.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7,987.00 Cr. (Mar 2025) to 8,209.00 Cr., marking an increase of 222.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 4,522.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,584.00 Cr. (Mar 2025) to 4,522.00 Cr., marking a decrease of 62.00 Cr..
- For CWIP, as of Sep 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 79.00 Cr. (Mar 2025) to 37.00 Cr., marking a decrease of 42.00 Cr..
- For Investments, as of Sep 2025, the value is 2,044.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,976.00 Cr. (Mar 2025) to 2,044.00 Cr., marking an increase of 68.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,607.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,348.00 Cr. (Mar 2025) to 1,607.00 Cr., marking an increase of 259.00 Cr..
- For Total Assets, as of Sep 2025, the value is 8,209.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,987.00 Cr. (Mar 2025) to 8,209.00 Cr., marking an increase of 222.00 Cr..
Notably, the Reserves (5,497.00 Cr.) exceed the Borrowings (637.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 40.00 | 95.00 | 495.00 | -246.00 | 372.00 | -141.00 | 390.00 | 352.00 | -512.00 | -282.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60 | 58 | 60 | 56 | 50 | 43 | 29 | 23 | 17 | 24 |
| Inventory Days | 99 | 94 | 147 | 99 | 92 | 88 | 101 | 111 | 93 | 110 |
| Days Payable | 99 | 125 | 154 | 134 | 126 | 111 | 101 | 119 | 86 | 115 |
| Cash Conversion Cycle | 60 | 27 | 53 | 22 | 17 | 21 | 29 | 15 | 25 | 19 |
| Working Capital Days | 89 | 81 | 98 | 96 | 107 | 10 | 4 | 5 | -1 | -3 |
| ROCE % | 11% | 18% | 24% | 11% | 5% | 13% | 11% | -4% | -0% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Regular Savings Fund | 75,047 | 0.18 | 5.96 | 75,047 | 2025-04-22 17:25:34 | 0% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 31,263 | 0.18 | 2.48 | 31,263 | 2025-04-22 17:25:34 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -8.87 | -32.25 | 55.78 | 76.22 | 22.57 |
| Diluted EPS (Rs.) | -8.87 | -32.25 | 55.78 | 76.22 | 22.57 |
| Cash EPS (Rs.) | 55.57 | 33.38 | 115.99 | 103.46 | 46.46 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 772.02 | 827.30 | 835.97 | 803.30 | 731.86 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 772.02 | 827.30 | 835.97 | 803.30 | 731.86 |
| Revenue From Operations / Share (Rs.) | 554.60 | 518.34 | 615.01 | 511.82 | 330.82 |
| PBDIT / Share (Rs.) | 61.62 | 30.79 | 157.51 | 140.60 | 57.96 |
| PBIT / Share (Rs.) | 8.21 | -20.60 | 119.92 | 113.67 | 34.21 |
| PBT / Share (Rs.) | 1.32 | -26.67 | 117.27 | 112.83 | 32.11 |
| Net Profit / Share (Rs.) | 2.15 | -18.01 | 78.39 | 76.52 | 22.72 |
| NP After MI And SOA / Share (Rs.) | -8.87 | -32.25 | 55.78 | 76.22 | 22.57 |
| PBDIT Margin (%) | 11.11 | 5.93 | 25.61 | 27.47 | 17.51 |
| PBIT Margin (%) | 1.47 | -3.97 | 19.49 | 22.20 | 10.34 |
| PBT Margin (%) | 0.23 | -5.14 | 19.06 | 22.04 | 9.70 |
| Net Profit Margin (%) | 0.38 | -3.47 | 12.74 | 14.95 | 6.86 |
| NP After MI And SOA Margin (%) | -1.59 | -6.22 | 9.06 | 14.89 | 6.82 |
| Return on Networth / Equity (%) | -1.14 | -3.89 | 6.67 | 9.48 | 3.08 |
| Return on Capital Employeed (%) | 0.85 | -2.07 | 11.75 | 11.52 | 3.84 |
| Return On Assets (%) | -0.81 | -2.95 | 4.91 | 7.01 | 2.31 |
| Long Term Debt / Equity (X) | 0.05 | 0.05 | 0.07 | 0.09 | 0.08 |
| Total Debt / Equity (X) | 0.09 | 0.08 | 0.09 | 0.10 | 0.08 |
| Asset Turnover Ratio (%) | 0.50 | 0.46 | 0.55 | 0.49 | 0.37 |
| Current Ratio (X) | 1.13 | 1.23 | 1.68 | 1.49 | 1.78 |
| Quick Ratio (X) | 0.60 | 0.67 | 1.13 | 1.01 | 1.41 |
| Inventory Turnover Ratio (X) | 9.12 | 6.75 | 6.45 | 6.97 | 6.16 |
| Dividend Payout Ratio (NP) (%) | -156.19 | -73.02 | 17.92 | 10.49 | 35.44 |
| Dividend Payout Ratio (CP) (%) | 31.08 | 123.03 | 10.70 | 7.75 | 17.27 |
| Earning Retention Ratio (%) | 256.19 | 173.02 | 82.08 | 89.51 | 64.56 |
| Cash Earning Retention Ratio (%) | 68.92 | -23.03 | 89.30 | 92.25 | 82.73 |
| Interest Coverage Ratio (X) | 8.95 | 5.07 | 59.43 | 168.00 | 27.53 |
| Interest Coverage Ratio (Post Tax) (X) | 1.31 | -1.97 | 30.58 | 92.43 | 11.79 |
| Enterprise Value (Cr.) | 4670.05 | 5324.43 | 4435.11 | 6873.06 | 2607.27 |
| EV / Net Operating Revenue (X) | 1.15 | 1.40 | 0.98 | 1.83 | 1.07 |
| EV / EBITDA (X) | 10.32 | 23.55 | 3.83 | 6.66 | 6.13 |
| MarketCap / Net Operating Revenue (X) | 1.04 | 1.30 | 0.95 | 1.75 | 1.04 |
| Retention Ratios (%) | 256.19 | 173.02 | 82.07 | 89.50 | 64.55 |
| Price / BV (X) | 0.75 | 0.81 | 0.70 | 1.12 | 0.47 |
| Price / Net Operating Revenue (X) | 1.04 | 1.30 | 0.95 | 1.75 | 1.04 |
| EarningsYield | -0.01 | -0.04 | 0.09 | 0.08 | 0.06 |
After reviewing the key financial ratios for Gujarat Alkalies & Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -8.87. This value is below the healthy minimum of 5. It has increased from -32.25 (Mar 24) to -8.87, marking an increase of 23.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is -8.87. This value is below the healthy minimum of 5. It has increased from -32.25 (Mar 24) to -8.87, marking an increase of 23.38.
- For Cash EPS (Rs.), as of Mar 25, the value is 55.57. This value is within the healthy range. It has increased from 33.38 (Mar 24) to 55.57, marking an increase of 22.19.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 772.02. It has decreased from 827.30 (Mar 24) to 772.02, marking a decrease of 55.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 772.02. It has decreased from 827.30 (Mar 24) to 772.02, marking a decrease of 55.28.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 554.60. It has increased from 518.34 (Mar 24) to 554.60, marking an increase of 36.26.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 61.62. This value is within the healthy range. It has increased from 30.79 (Mar 24) to 61.62, marking an increase of 30.83.
- For PBIT / Share (Rs.), as of Mar 25, the value is 8.21. This value is within the healthy range. It has increased from -20.60 (Mar 24) to 8.21, marking an increase of 28.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.32. This value is within the healthy range. It has increased from -26.67 (Mar 24) to 1.32, marking an increase of 27.99.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from -18.01 (Mar 24) to 2.15, marking an increase of 20.16.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -8.87. This value is below the healthy minimum of 2. It has increased from -32.25 (Mar 24) to -8.87, marking an increase of 23.38.
- For PBDIT Margin (%), as of Mar 25, the value is 11.11. This value is within the healthy range. It has increased from 5.93 (Mar 24) to 11.11, marking an increase of 5.18.
- For PBIT Margin (%), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 10. It has increased from -3.97 (Mar 24) to 1.47, marking an increase of 5.44.
- For PBT Margin (%), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 10. It has increased from -5.14 (Mar 24) to 0.23, marking an increase of 5.37.
- For Net Profit Margin (%), as of Mar 25, the value is 0.38. This value is below the healthy minimum of 5. It has increased from -3.47 (Mar 24) to 0.38, marking an increase of 3.85.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -1.59. This value is below the healthy minimum of 8. It has increased from -6.22 (Mar 24) to -1.59, marking an increase of 4.63.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.14. This value is below the healthy minimum of 15. It has increased from -3.89 (Mar 24) to -1.14, marking an increase of 2.75.
- For Return on Capital Employeed (%), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 10. It has increased from -2.07 (Mar 24) to 0.85, marking an increase of 2.92.
- For Return On Assets (%), as of Mar 25, the value is -0.81. This value is below the healthy minimum of 5. It has increased from -2.95 (Mar 24) to -0.81, marking an increase of 2.14.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.08 (Mar 24) to 0.09, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.50. It has increased from 0.46 (Mar 24) to 0.50, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 1.5. It has decreased from 1.23 (Mar 24) to 1.13, marking a decrease of 0.10.
- For Quick Ratio (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 1. It has decreased from 0.67 (Mar 24) to 0.60, marking a decrease of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.12. This value exceeds the healthy maximum of 8. It has increased from 6.75 (Mar 24) to 9.12, marking an increase of 2.37.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -156.19. This value is below the healthy minimum of 20. It has decreased from -73.02 (Mar 24) to -156.19, marking a decrease of 83.17.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 31.08. This value is within the healthy range. It has decreased from 123.03 (Mar 24) to 31.08, marking a decrease of 91.95.
- For Earning Retention Ratio (%), as of Mar 25, the value is 256.19. This value exceeds the healthy maximum of 70. It has increased from 173.02 (Mar 24) to 256.19, marking an increase of 83.17.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 68.92. This value is within the healthy range. It has increased from -23.03 (Mar 24) to 68.92, marking an increase of 91.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.95. This value is within the healthy range. It has increased from 5.07 (Mar 24) to 8.95, marking an increase of 3.88.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 3. It has increased from -1.97 (Mar 24) to 1.31, marking an increase of 3.28.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4,670.05. It has decreased from 5,324.43 (Mar 24) to 4,670.05, marking a decrease of 654.38.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.15. This value is within the healthy range. It has decreased from 1.40 (Mar 24) to 1.15, marking a decrease of 0.25.
- For EV / EBITDA (X), as of Mar 25, the value is 10.32. This value is within the healthy range. It has decreased from 23.55 (Mar 24) to 10.32, marking a decrease of 13.23.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.30 (Mar 24) to 1.04, marking a decrease of 0.26.
- For Retention Ratios (%), as of Mar 25, the value is 256.19. This value exceeds the healthy maximum of 70. It has increased from 173.02 (Mar 24) to 256.19, marking an increase of 83.17.
- For Price / BV (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.81 (Mar 24) to 0.75, marking a decrease of 0.06.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.30 (Mar 24) to 1.04, marking a decrease of 0.26.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 24) to -0.01, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gujarat Alkalies & Chemicals Ltd:
- Net Profit Margin: 0.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.85% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1.14% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.31
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.6
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 25 (Industry average Stock P/E: 4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.38%
Fundamental Analysis of Gujarat Alkalies & Chemicals Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Caustic Soda/Soda Ash | P.O. : Ranoli Vadodra District Gujarat 391350 | investor_relations@gacl.co.in http://www.gacl.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Hasmukh Adhia | Chairman |
| Mr. P Swaroop | Managing Director |
| Mr. Rajiv Lochan Jain | Independent Director |
| Mr. S B Dangayach | Independent Director |
| Mr. Nitin Shukla | Independent Director |
| Mr. Shridevi Shukla | Independent Director |
| Mr. M K Das | Director |
| Mr. J P Gupta | Director |
Gujarat Alkalies & Chemicals Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹798.95 |
| Previous Day | ₹811.35 |
FAQ
What is the intrinsic value of Gujarat Alkalies & Chemicals Ltd?
Gujarat Alkalies & Chemicals Ltd's intrinsic value (as of 07 December 2025) is 178925.55 which is 34508.42% higher the current market price of 517.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 3,795 Cr. market cap, FY2025-2026 high/low of 823/484, reserves of ₹5,497 Cr, and liabilities of 8,209 Cr.
What is the Market Cap of Gujarat Alkalies & Chemicals Ltd?
The Market Cap of Gujarat Alkalies & Chemicals Ltd is 3,795 Cr..
What is the current Stock Price of Gujarat Alkalies & Chemicals Ltd as on 07 December 2025?
The current stock price of Gujarat Alkalies & Chemicals Ltd as on 07 December 2025 is 517.
What is the High / Low of Gujarat Alkalies & Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gujarat Alkalies & Chemicals Ltd stocks is 823/484.
What is the Stock P/E of Gujarat Alkalies & Chemicals Ltd?
The Stock P/E of Gujarat Alkalies & Chemicals Ltd is 25,303.
What is the Book Value of Gujarat Alkalies & Chemicals Ltd?
The Book Value of Gujarat Alkalies & Chemicals Ltd is 759.
What is the Dividend Yield of Gujarat Alkalies & Chemicals Ltd?
The Dividend Yield of Gujarat Alkalies & Chemicals Ltd is 3.06 %.
What is the ROCE of Gujarat Alkalies & Chemicals Ltd?
The ROCE of Gujarat Alkalies & Chemicals Ltd is 0.34 %.
What is the ROE of Gujarat Alkalies & Chemicals Ltd?
The ROE of Gujarat Alkalies & Chemicals Ltd is 1.13 %.
What is the Face Value of Gujarat Alkalies & Chemicals Ltd?
The Face Value of Gujarat Alkalies & Chemicals Ltd is 10.0.